Article
A Selective Biligand Inhibitor of CK2 Increases Caspase‐3 Activity in Cancer Cells and Inhibits Platelet Aggregation
24 Aug 2017
Abstract excerpt
Abstract Cancer cells express high levels of CK2, and its inhibition leads to apoptosis. CK2 has therefore emerged as a new drug target for cancer therapy. A biligand inhibitor ARC‐772 was constructed by conjugating 4‐(2‐amino‐1,3‐thiazol‐5‐yl)benzoic acid and a carboxylate‐rich peptoid. ARC‐772 was found to bind CK2 with a Kd value of 0.3 nm and showed remarkable CK2 inhibitory selectivity in a panel of 140...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
